Administration of the AT1-selective antagonist candesartan (CDS), which started at 6-weeks, nearly abolished both cardiac hypertrophy and fibrosis with improvement of %FS at 24-weeks (Fig 3A–3D). The gene discussed is AGTR1; the disease is cardiac hypertrophy.